{
  "id": 11388836,
  "title": "En panne d’innovation, Sanofi puise dans la R&D de l’américain Regeneron pour se relancer",
  "url": "https://urgent.news/2026/10/02/en-panne-dinnovation-sanofi-puise-dans-la-r-d-de-lamericain-regeneron",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-02T07:30:12.000Z",
  "source": {
    "name": "Le Monde Economie",
    "slug": "le-monde-economie",
    "url": "https://www.lemonde.fr/economie/article/2026/10/02/en-panne-d-innovation-sanofi-puise-dans-la-r-d-de-l-americain-regeneron-pour-se-relancer_6787076_3234.html"
  },
  "original_language": "fr",
  "account": null,
  "summary": "En annonçant jeudi un important accord de collaboration avec la société Regeneron, Sanofi met la main sur des anticorps appelés à prendre le relais de son médicament vedette, le Dupixent, dont le brevet expirera en 2031.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Sanofi gains after expanding Regeneron partnership with $8 billion deal",
        "url": "https://urgent.news/2026/10/01/sanofi-gains-after-expanding-regeneron-partnership-with-8-billion-deal",
        "published": "2026-10-01T07:25:58.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}